Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Inotuzumab/bosutinib treat R/R Ph+ ALL, CML in blast phase

Publish date:: June 29, 2020

Key clinical point: Inotuzumab ozogamicin plus bosutinib may be effective against relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic and chronic myeloid leukemias in blast phase.

Major finding: The median overall survival was 15.4 months.

Study details: Phase 1/2 trial in 18 patients with Ph+ ALL or CML.

Disclosures: Dr. Jain has disclosed consultancy, honoraria, advisory board/committee activity, and research funding from Pfizer, maker of inotuzumab ozogamicin and bosutinib.

Citation:

Jain N et al. EHA Congress, Abstract EP396.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in ALL

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo,

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

Study: Complications from childhood ALL and its treatment are common, but can be managed,